» Articles » PMID: 26405601

Poor Survival in Glioblastoma Patients is Associated with Early Signs of Immunosenescence in the CD4 T-cell Compartment After Surgery

Overview
Journal Oncoimmunology
Date 2015 Sep 26
PMID 26405601
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with glioblastoma multiforme (GBM) are immunosuppressed and have a broad range of immunological defects in both innate and adaptive immune responses. GBMs are frequently infected with human cytomegalovirus (HCMV), a virus capable of causing immunosuppression. In 42 HCMV-positive GBM patients in a clinical trial (VIGAS), we investigated T-cell phenotypes in the blood and assessed their relation to survival. Blood was collected before and 3, 12, and 24 weeks after surgery, and the frequency of T-cell subsets was compared with that in 26 age-matched healthy controls. GBM patients had lower levels of CD3 cells than the controls, but had significantly higher levels of CD4CD28 T cells before and 3 and 12 weeks after surgery and increased levels of CD4CD57 and CD4CD57CD28 T cells at all-time points. These T-cell subsets were associated with both immunosenescence and HCMV infection. GBM patients also had higher levels of γδ T cells at all-times after surgery and lower levels of CD4CD25 cells before and 3 weeks after surgery than healthy controls. Overall survival was significantly shorter in patients with higher levels of CD4CD28 T cells ( 0.025), CD4CD57 T ( 0.025) cells, and CD4CD28CD57CD28 T cells ( 0.0004) at 3 weeks after surgery. Our findings indicate that signs of immunosenescence in the CD4 compartment are associated with poor prognosis in patients with HCMV-positive GBMs and may reflect the HCMV activity in their tumors.

Citing Articles

Pediatric brain tumor patients display altered immune activation and reduced lymphopoiesis at the onset of disease.

Rosichini M, Del Baldo G, De Luca C, Benini F, Genah S, Vinci M NPJ Precis Oncol. 2024; 8(1):269.

PMID: 39567679 PMC: 11579487. DOI: 10.1038/s41698-024-00755-y.


Unravelling the mosaic: Epigenetic diversity in glioblastoma.

Lucchini S, Constantinou M, Marino S Mol Oncol. 2024; 18(12):2871-2889.

PMID: 39148319 PMC: 11619803. DOI: 10.1002/1878-0261.13706.


Senescent T Cells in Age-Related Diseases.

Yu P, Zhou M, Liu Y, Du J Aging Dis. 2024; .

PMID: 38502582 PMC: 11745454. DOI: 10.14336/AD.2024.0219.


T Cell Features in Glioblastoma May Guide Therapeutic Strategies to Overcome Microenvironment Immunosuppression.

Losurdo A, Di Muzio A, Cianciotti B, Dipasquale A, Persico P, Barigazzi C Cancers (Basel). 2024; 16(3).

PMID: 38339353 PMC: 10854506. DOI: 10.3390/cancers16030603.


The immunological landscape of peripheral blood in glioblastoma patients and immunological consequences of age and dexamethasone treatment.

Dusoswa S, Verhoeff J, van Asten S, Lubbers J, van den Braber M, Peters S Front Immunol. 2024; 15:1343484.

PMID: 38318180 PMC: 10839779. DOI: 10.3389/fimmu.2024.1343484.


References
1.
Hegde M, Bielamowicz K, Ahmed N . Novel approaches and mechanisms of immunotherapy for glioblastoma. Discov Med. 2014; 17(93):145-54. View

2.
Kobayashi T, Okamoto S, Iwakami Y, Nakazawa A, Hisamatsu T, Chinen H . Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. Inflamm Bowel Dis. 2007; 13(7):837-46. DOI: 10.1002/ibd.20113. View

3.
van Leeuwen E, Remmerswaal E, Vossen M, Rowshani A, Wertheim-van Dillen P, van Lier R . Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol. 2004; 173(3):1834-41. DOI: 10.4049/jimmunol.173.3.1834. View

4.
Pourgheysari B, Khan N, Best D, Bruton R, Nayak L, Moss P . The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol. 2007; 81(14):7759-65. PMC: 1933343. DOI: 10.1128/JVI.01262-06. View

5.
Betjes M, Meijers R, de Wit L, Litjens N . A killer on the road: circulating CD4(+)CD28null T cells as cardiovascular risk factor in ESRD patients. J Nephrol. 2011; 25(2):183-91. DOI: 10.5301/jn.5000057. View